Journal Browser Advanced Search Help
Journal Browser Advanced search HELP
J Gynecol Oncol. 2014 Apr;25(2):136-147. English. Review. https://doi.org/10.3802/jgo.2014.25.2.136
DeLeon MC , Ammakkanavar NR , Matei D .
Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, IN, USA. dmatei@iupui.edu
Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA.
Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA.
VA Roudebush Hospital, Indiana University School of Medicine, Indianapolis, IN, USA.
Abstract

Endometrial cancer is a common gynecologic malignancy typically diagnosed at early stage and cured with surgery alone. Adjuvant therapy is tailored according to the risk of recurrence, estimated based on the International Federation of Gynecology and Obstetrics (FIGO) stage and other histological factors. The objective of this manuscript is to review the evidence guiding adjuvant therapy for early stage and locally advanced uterine cancer. For patients with early stage disease, minimizing toxicity, while preserving outstanding cure rates remains the major goal. For patients with locally advanced endometrial cancer optimal combined regimens are being defined. Risk stratification based on molecular traits is under development and may aid refine the current risk prediction model and permit personalized approaches for women with endometrial cancer.

Copyright © 2019. Korean Association of Medical Journal Editors.